REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2016, the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) changed the title of George D. Yancopoulos, M.D., Ph.D. from President of Regeneron Laboratories and Chief Scientific Officer of Regeneron to President and Chief Scientific Officer of Regeneron. This change, which was effective immediately, was meant to better align Dr. Yancopoulos’s title with the scope of his current responsibilities at the Company. Leonard S. Schleifer, M.D., Ph.D. continues to serve as President and Chief Executive Officer of the Company.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

In connection with the change in Dr. Yancopoulos’s title, as described above, on December 16, 2016, the Board, based upon the recommendation of the Corporate Governance and Compliance Committee of the Board, amended and restated Regeneron’s By-Laws to (i) change the title of President to Chief Executive Officer, (ii) allow for the Board to appoint one or more Presidents, (iii) describe the role of Presidents, and (iv) implement other minor changes, including conforming changes resulting from the revisions described above. The amendment and restatement of the By-Laws was effective immediately.

The foregoing summary of the amendment and restatement of the Company’s By-Laws is qualified in its entirety by the full text of the Amended and Restated By-Laws, which is attached as Exhibit 3.2 hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

3.2 Amended and Restated By-Laws effective December 16, 2016.


About REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Recent Trading Information

REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) closed its last trading session down -5.96 at 365.06 with 747,230 shares trading hands.